Chinese Journal of Magnetic Resonance ›› 2019, Vol. 36 ›› Issue (4): 517-524.doi: 10.11938/cjmr20192774

• Articles • Previous Articles     Next Articles

Analysis of Metabolic Characteristics of SIRT7 Low Expression Glioma Cell Line Using NMR-Based Metabonomics

SHAO Wei1,2, LIN Qing-yuan1, YANG Wen-sheng1, HUANG Cai-hua3, LIN Dong-hai1,2   

  1. 1. Chenggong Hospital Affiliated Xiamen University, Xiamen 361005, China;
    2. College of Chemistry and Chemical Engineering, High-Field Nuclear Magnetic Resonance Research Center, Xiamen University, Xiamen 361005, China;
    3 Research and Communication Center of Exercise and Health, Xiamen University of Technology, Xiamen 361024, China
  • Received:2019-08-06 Online:2019-12-05 Published:2019-10-08

Abstract: Tumor is a metabolic disease. The effect of oncogene expression on the metabolism of cancer cells is one of the hotspots in cancer research. In this study, 1H NMR-based metabonomics analysis was used to explore the metabolic characteristics of glioma cell lines with low expression of SIRT7, and to identify the characteristic metabolites and metabolic pathways related to the expression of SIRT7. The results showed that there were significant differences in metabolic profiles between the SIRT7 low expression group and the control group, and 22 aqueous metabolites were found to vary significantly. Compared with the control group, the concentration of 12 metabolites including lactate, glycine, and glutamate, and so on, increased in SIRT7 low expression glioma cell lines, while the concentration of 10 metabolites such as valine, leucine, lysine, et al. decreased. Pathway enrichment analysis indicated that the metabolic pathways of aminoacyl-tRNA biosynthesis, tyrosine metabolism, and so on, were closely related to the low expression of SIRT7. The results provide a theoretical basis for further mechanism elucidation of SIRT7 regulating glioma cell metabolism.

Key words: proton nuclear magnetic resonance, metabonomics, Sirtuin7, characteristic metabolites, metabolic pathways

CLC Number: